Newsletter December 2015 - No 51
View this email in your browser

Upcoming events

Accelerated innovation and go-to-market by joining forces
Stockholm, January 19

After work: Health economics - why think value early on
Uppsala, January 19

London, January 3

CHaSE 2016, the career fair at Karolinska Institutet
Stockholm, February 11

Gothenburg, April 5-7

Course: Biobanking as a resource for biomedical research
Stockholm, April 18-22, 2016

Anglo-Nordic Life Science Conference XIII
London, May 19

To all events >> 

Core facilities in the region

Did you know that you can find services provided by academic core facilities on Tools of Science? Cell analysis, bioproduction, or use of biobanks and registers are just a few of the facilities listed on the site. All academic core facilities on the site are commercially operated and most are open for the industry to use. Who knows, perhaps it’s time to evaluate a new service provider during 2016, and perhaps it’s time for an academic one?

Tools of Science

SWElife call

SWElife have different calls for proposals, aiming to stimulate the prevention, treatment or means to improve the quality of life for persons who risk being, or already have been, affected by a widespread disease.

This strategic innovation program is a national initiative to co-ordinate and develop stable research and innovation processes for life science in Sweden.

Read the full call here >>

Accelerating Business

“Healthcare will be among the industries in which digitalization will have the largest impact”, Kenneth Salonius, co-founder of Vertical accelerator says.

Read the full blog post >>

Holiday greetings from Ylva

It's holiday season and time to reflect on Swedish traditions. This time, I'm not thinking of Lucia, sour herring premiere and glögg parties, but of protein research and production of biopharmaceuticals.

This has been a strong industry for Sweden since the Nobel prize of Tiselius and Svedberg, and last week we heard the great news that the Knut and Alice Wallenberg Foundation has decided to allocate 320 MSEK to a research center for protein research - the Wallenberg Centre for Protein Research, WCPR. Together with funding from Uppsala University, KTH, Chalmers and AstraZeneca, the effort amounts to 510 MSEK during 2016-2023. This definitely places Swedish protein research on the international arena.

For AstraZeneca, and the company's global division for research and development of protein pharmaceuticals - Medimmune - the ageeement is a three-year collaboration with the Wallenberg Centre for Protein Research. The goal is to develop new technologies for production of biologicals and to identify new targets. More specifically, it is proteins in the secretome, i.e. those that are secreted by cells, or that are present on the cell surface, that will be investigated. 

As if those engagements did not prove the point - on December 3, GE Healthcare announced a 870 MSEK investment in their production plant in Uppsala. The investment doubles the present production capacity for chromatography media, that is to say, products that are used for purification of biopharmaceuticals.

Thus, substantial funding form academia and industry together. In order to grasp the magnitude of the life science industry - did you know that export of life science products amounts to 15 per cent of the total Swedish net export? Only pharmaceuticals are exported to a value of 6 billion SEK per month. That is one billion SEK more than the export of iron and steel.
Protein research is a strong sector for Swedish life science - and life science is an engine of export of Sweden. 
With that, I'd like to wish you a happy holiday season!

Ylva Williams
CEO of Stockholm Science City Foundation

PS. If you are interested to read about the work of Stockholm Science City Foundation in the media, check out this >>

Reflections of an Eisenhower Fellow visiting Stockholm Science City

"As an Eisenhower Fellow for 2015, I was granted an opportunity to study health innovations in very different environments - I spent the spring in Kenya, studying care in the urban slums and in the peri-urban communities, understanding effective private efforts to bring basic primary and maternal care to a population that has very few health resources. Sweden, on the other hand, represented an opportunity to understand how an intentionally designed, and demonstrably effective, system is structured and managed." 

Secure your company presentation at BIO Europe Spring

Which category suits your business best?
  • Biotech Company 
  • Midsize Pharma 
  • Next Generation 
  • Academic Innovators
Company Presentation Information >>

Sweden BIO CEO Summit  

On December 2nd, decision makers from the life science industry gathered for SwedenBIOs CEO Summit, this year focusing on how to make you life science company an attractive business partner. We got the opportunity to listen to Anders Åberg, CEO of Sprint Bioscience, and Carl Borrebaeck, co-founder of Alligator Bioscience, who shared their experiences of the journeys from start-up companies to the multi-billion deals with big pharma that both companies closed during 2015.

Sweden BIO also released The Swedish Drug Development Pipeline2015. This annual report follows the trends of developing life science companies in Sweden over time. 
Follow us on Twitter @SthlmLife
Follow us on Instagram. @stockholmlife
Join the Tools of Science LinkedIn group for discussions with academic researchers, core facilities, CRO's and other life science companies.
Visit the website of Stockholm Science City Foundation
Visit the website of Stockholm Life
Forward to Friend
Copyright ©2015 Stockholm Science City Foundation, All rights reserved.
unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp